NCT07203833 Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
| NCT ID | NCT07203833 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Vasorin |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2025-10-19 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 144 participants in total. It began in 2025-10-19 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.
Eligibility Criteria
Inclusion Criteria: * Adults over 18 years. * Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie. * Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\>38.3) with a documented or suspected infection * Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock Exclusion Criteria: * Pregnant women * Group 1 : No evidence of suspected or documented infection * Group 2 : Presence of fever and/or suspected infection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07203833 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vasorin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07203833 currently recruiting?
Yes, NCT07203833 is actively recruiting participants. Contact the research team at maizel.julien@chu-amiens.fr for enrollment information.
Where is the NCT07203833 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT07203833 clinical trial?
NCT07203833 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 144 participants.